A New Headset for Depression Treatment Hits US Shores

The recent approval of Flow Neuroscience’s wearable headset for treating depression marks a significant shift in the way we approach mental health care. With one in six American adults taking antidepressant medication, the need for alternative treatments has never been more pressing.

The headset itself is an intriguing device that provides low-intensity electrical stimulation to the left frontal lobe of the brain, an area critical in regulating mood and emotions. This targeted approach is similar to transcranial magnetic stimulation (TMS), a well-established treatment for depression that uses magnetic fields to activate neurons. Unlike TMS, which requires multiple sessions at a clinic over several weeks, Flow’s device can be used conveniently from home.

A clinical trial involving 174 people with major depressive disorder found promising results: 45 percent of participants experienced symptom remission after using the device for 10 weeks, compared to just 22 percent in the control group. The study demonstrates the potential efficacy of this new technology.

However, concerns about accessibility and cost are already being raised. At $2,200 for a 10-week course, plus an additional $325 per month thereafter, Flow’s headset is likely out of reach for many patients who need it most. This raises questions about how those without insurance or significant financial means will be able to access this treatment.

Vinod Khosla, an early investor in Flow and a proponent of nonchemical approaches to mental health care, believes that patients would prefer not to take medication if given the choice. While this may be true for some individuals, it’s essential to acknowledge that medication has been a lifeline for countless people struggling with depression.

More than 65,000 people in Europe have already used Flow’s device, and the UK’s National Health Service is piloting its use. This raises questions about why similar programs aren’t being implemented here in the US. Is it because of the high cost, or are there other factors at play?

Flow CEO Daniel Månsson has stated that his goal is to create a convenient and safe treatment option for patients. As we move forward with this technology, it’s crucial to prioritize accessibility and equity. We must ensure that this new frontier in mental health care doesn’t widen the gap between those who have access to resources and those who don’t.

The complexities of treating depression demand a comprehensive approach, encompassing medication, therapy, and lifestyle changes. This new technology has the potential to be a game-changer, but only if it’s made available to those who need it most.